Publicaciones
-
Cristina Larrosa Espinosa, Simao-Rafael M, Salvador-Marcos N, Muñoz JP, Lavarino C, Chantada G and Mora J.
Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy
Frontiers in Pediatrics . 12: 1509645-1509645. Nº de citas: 4
-
Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J.
Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes
PEDIATRIC BLOOD & CANCER . 71(10): . Nº de citas: 1
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de citas: 3
-
Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Cancers . 15(19): . Nº de citas: 21
-
Cristina Larrosa Espinosa, Mora J and Cheung NK.
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
Cancers . 15(14): . Nº de citas: 20
-
Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
Cancers . 15(9): . Nº de citas: 21
